Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on trackAug 6Quarterly updateJanux TherapeuticsJANX007